Millipore Sigma Vibrant Logo

MABC1126-100UG Anti-EGFRvIII mutation Antibody, clone L8A4

View Products on Sigmaaldrich.com
MABC1126-100UG
100 μg  
Recuperando precio...
No pudo obtenerse el precio
La cantidad mínima tiene que ser múltiplo de
Maximum Quantity is
Al finalizar el pedido Más información
Ahorró ()
 
Solicitar precio
Disponibilidad a confirmar
Disponibilidad a confirmar
Ingrese cantidad 
Suspendido
Cantidades limitadas disponibles
Debe confirmarse disponibilidad
    El resto: se avisará
      El resto: se avisará
      Se avisará
      Póngase en contacto con el Servicio de Atención al Cliente
      Contact Customer Service

       

      Póngase en contacto con el Servicio de Atención al Cliente

      Descripción

      Replacement Information

      Tabla espec. clave

      Species ReactivityKey ApplicationsHostFormatAntibody Type
      HELISA, FC, ICC, IHC, IH(P), WBMPurifiedMonoclonal Antibody
      Description
      Catalogue NumberMABC1126-100UG
      DescriptionAnti-EGFRvIII mutation Antibody, clone L8A4
      Alternate Names
      • Epidermal Growth Factor Receptor vIII
      Background InformationEpidermal growth factor receptor (UniProt: P00533; also known as EC:2.7.10.1, Proto-oncogene c-ErbB-1, Receptor tyrosine-protein kinase erbB-1) is encoded by the EGFR (also known as ERBB, ERBB1, HER1) gene (Gene ID: 1956) in human. EGFR is a single-pass type 1 membrane protein that is ubiquitously expressed. It is synthesized with a 24 amino acids signal peptide that is subsequently cleaved. It contains an extracellular domain (aa 25-645) a transmembrane domain (aa 646-668), and a cytoplasmic domain (aa 669-1210). Upon binding of EGF, the receptor is phosphorylated and recruits adapter proteins to turn on downstream signaling cascades. EGFR is commonly overexpressed and is mutated in many human malignancies and is often associated with aggressive phenotypes. The most common truncated EGFR is the variant III EGFR deletion mutant (EGFRvIII), containing an inframe deletion of exons 2 7 (801 bp) from the extracellular domain. EGFRvIII mutation is reported in about 5% of human lung squamous cell carcinoma (SCC). It has also been suggested that EGFRvIII potentially plays an essential role in the human NSCLC tumor initiation and maintenance. Drugs such as Gefitinib, erlotnib, and HKI-272 are shown to inhibit the growth of EGFRvIII transformed cells and tumor growth. This monoclonal antibody binds specifically to the epidermal growth factor receptor variant III (EGFRvIII), which is present on gliomas, but not normal tissues, and is internalized rapidly after receptor binding. (Ref.: Ji, H., et al. (2006). Proc. Natl. Acad. Sci. USA 103(20); 7817-7822; Hens, M., et al. (2010). Nucl. Med. Biol. 37(7); 741-750).
      References
      Product Information
      FormatPurified
      PresentationPurified mouse monoclonal antibody IgG1 in PBS without azide.
      Applications
      ApplicationAnti-EGFRvIII mutation, clone L8A4, Cat. No. MABC1126, is a mouse monoclonal antibody that detects Epidermal Growth Factor Receptor variant III and has been tested for use in ELISA, Flow Cytometry, Immunocytochemistry, Immunohistochemistry, Immunohistochemistry (Paraffin), and Western Blotting.
      Key Applications
      • ELISA
      • Flow Cytometry
      • Immunocytochemistry
      • Immunohistochemistry
      • Immunohistochemistry (Paraffin)
      • Western Blotting
      Application NotesWestern Blotting Analysis: A representative lot detected EGFRvIII mutation in Western Blotting applications (Wikstrand, C.J., et. al. (1998). J Neuroviral. 4(2):148-58; Grandi, P., et. al. (2010). Cancer Gene Ther. 17(9):655-63; Wikstrand, C.J., et. al. (1995). Cancer Res. 55(14):3140-8).

      Immunohistochemistry (Paraffin) Analysis: A representative lot detected EGFRvIII mutation in Immunohistochemistry applications (Mellinghoff, I.K., et. al. (2005). N Engl J Med. 353(19):2012-24; Sok, J.C., et. al. (2006). Clin Cancer Res. 12(17):5064-73).

      Immunohistochemistry Analysis: A representative lot detected EGFRvIII mutation in Immunohistochemistry applications (Wikstrand, C.J., et. al. (1998). J Neuroviral. 4(2):148-58; Wikstrand, C.J., et. al. (1995). Cancer Res. 55(14):3140-8).

      ELISA Analysis: A representative lot detected EGFRvIII mutation in ELISA applications (Wikstrand, C.J., et. al. (1998). J Neuroviral. 4(2):148-58; Wikstrand, C.J., et. al. (1995). Cancer Res. 55(14):3140-8).

      Flow Cytometry Analysis: A representative lot detected EGFRvIII mutation in Flow Cytometry applications (Wikstrand, C.J., et. al. (1998). J Neuroviral. 4(2):148-58; Wikstrand, C.J., et. al. (1995). Cancer Res. 55(14):3140-8).

      Immunocytochemistry Analysis: A representative lot detected EGFRvIII mutation in Immunocytochemistry applications (Wikstrand, C.J., et. al. (1998). J Neuroviral. 4(2):148-58; Batra, S.K., et. al. (1995). Cell Growth Differ. 6(10):1251-9).
      Biological Information
      ImmunogenKLH-conjugated linear peptide corresponding to the predicted amino acid sequence of 14 amino acids at the fusion junction combined with cultured HC2 20 d2 cells.
      CloneL8A4
      ConcentrationPlease refer to lot specific datasheet.
      HostMouse
      SpecificityClone L8A4 specifically binds to EGFRvIII, a mutated form of EGFR.
      IsotypeIgG1κ
      Species Reactivity
      • Human
      Species Reactivity NoteHuman.
      Antibody TypeMonoclonal Antibody
      Entrez Gene Number
      Gene Symbol
      • EGFR
      • ERBB
      • ERBB1
      • HER1
      Purification MethodProtein G purified
      UniProt Number
      Molecular Weight~145 kDa observed. Uncharacterized bands may be observed in some lysate(s).
      Physicochemical Information
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Quality AssuranceEvaluated by Western Blotting in NR6 cells expressing human EGFRvIII (NR6M).

      Western Blotting Analysis: 1 µg/mL of this antibody detected EGFRvIII mutation in NR6 cells expressing human EGFRvIII (NR6M).
      Usage Statement
      • Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
      Storage and Shipping Information
      Storage ConditionsStable for 1 year at -20°C from date of receipt.

      Handling Recommendations: Upon receipt and prior to removing the cap, centrifuge the vial and gently mix the solution. Aliquot into microcentrifuge tubes and store at -20°C. Avoid repeated freeze/thaw cycles, which may damage IgG and affect product performance.
      Packaging Information
      Material Size100 μg
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      Número de referencia GTIN
      MABC1126-100UG 04054839507267

      Documentation

      Anti-EGFRvIII mutation Antibody, clone L8A4 Ficha datos de seguridad (MSDS)

      Título

      Ficha técnica de seguridad del material (MSDS) 

      Anti-EGFRvIII mutation Antibody, clone L8A4 Certificados de análisis

      CargoNúmero de lote
      Anti-EGFRvIII mutation, clone L8A4 - 3163451 3163451
      Anti-EGFRvIII mutation, clone L8A4 - 3224552 3224552
      Anti-EGFRvIII mutation, clone L8A4 - 3388986 3388986
      Anti-EGFRvIII mutation, clone L8A4 - 3713361 3713361
      Anti-EGFRvIII mutation, clone L8A4 - 3731578 3731578
      Anti-EGFRvIII mutation, clone L8A4 - 3874285 3874285
      Anti-EGFRvIII mutation, clone L8A4 - 3949762 3949762
      Anti-EGFRvIII mutation, clone L8A4 - 4013366 4013366
      Anti-EGFRvIII mutation, clone L8A4 - 4107271 4107271
      Anti-EGFRvIII mutation, clone L8A4 Monoclonal Antibody Q3049674